Advertisement
Screener

Lexeo Therapeutics, Inc. (LXEO) Graph

LXEO Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $19.03M; Operating expenses $28.02M; Net income -$25.87M.
  • 2026-03-31: Revenue (m); Research and development $15.70M; Operating expenses $22.33M; Net income -$20.20M.
  • 2025-12-31: Revenue (m); Research and development $16.21M*; Operating expenses $23.12M*; Net income (m).
  • 2025-09-30: Revenue (m); Research and development $15.70M; Operating expenses $21.65M; Net income -$20.28M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$19.03M$28.02M-$25.87M
2026-03-31(m)$15.70M$22.33M-$20.20M
2025-12-31(m)$16.21M*$23.12M*(m)
2025-09-30(m)$15.70M$21.65M-$20.28M
2025-06-30(m)$14.72M$30.69M-$26.10M
2025-03-31(m)$17.17M$33.80M-$32.66M
2024-09-30(m)$23.42M$31.54M-$29.49M
2024-06-30(m)$16.56M$23.55M-$21.24M
2024-03-31(m)$15.74M$23.29M-$21.68M
2023-09-30(m)$17.25M$20.27M-$20.11M
2023-06-30(m)$11.24M$13.97M-$13.44M
2023-03-31(m)$16.44M$19.29M-$18.66M
2022-09-30$531.00K$15.36M$18.01M-$17.05M
2022-06-30(m)(m)(m)-$15.14M
2022-03-31(m)(m)(m)-$12.50M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$34.73M$50.35M-$46.06M
2025-06-30$31.89M$64.49M-$58.76M
2024-06-30$32.30M$46.84M-$42.92M
2023-06-30$27.67M$33.27M-$32.10M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30(m)$47.59M$86.14M-$79.04M
2024-09-30(m)$55.73M$78.38M-$72.41M
2023-09-30(m)$44.92M$53.54M-$52.21M
2022-09-30$654.00K$37.77M$45.97M-$44.70M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$63.80M$109.26M$0.00-$100.00M
2024-12-31(m)$74.09M$105.77M$0.00-$98.33M
2023-12-31(m)$53.13M$68.51M(m)-$66.39M
2022-12-31$654.00K$49.16M$61.16M(m)-$59.28M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35